ChemImage is applying molecular chemical imaging technology to develop a fast, non-invasive test to quantify the degree of a patient’s heart failure by detecting levels of peripheral edema.
The high level of readmission for many patients with heart disease is driven, in part, by the challenges in outpatient settings to quantify and manage peripheral edema in patients. That’s where we come in.
ChemImage is developing a rapid, non-invasive approach using short wave infrared (SWIR) molecular chemical imaging technology that permits physicians to quantify edema levels and therefore make better clinical decisions in the management of heart failure.
Heart Disease Facts:
- Heart failure is the leading cause of hospitalizations in the U.S for patients over age 65.
- The American Heart Association projects more than 8 million Americans will have heart failure by 2030.
- Heart failure accounts for more hospital admissions than all forms of cancer combined.
- 25% of heart failure patients will be readmitted within 30 days of discharge.
SWIR whole body diagnostic technology has application potential in hospitals, outpatient clinics, and for at-home testing.
In the event of peripheral edema, the ability to better classify patients with different levels of heart failure may allow physicians and their staff to more accurately identify specific treatment options, thereby decreasing the need for subsequent admissions.
